Literature DB >> 24442222

Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care.

Michael J Silverberg1, Wendy A Leyden, Lanfang Xu, Michael A Horberg, Chun R Chao, William J Towner, Leo B Hurley, Charles P Quesenberry, Daniel B Klein.   

Abstract

BACKGROUND: We sought to clarify the association of HIV infection and immunodeficiency on myocardial infarction (MI) risk.
METHODS: We conducted a cohort study from 1996 to 2009 of HIV-positive (HIV) and demographically matched HIV-negative (HIV) Kaiser Permanente California health plan members. Rate ratios (RRs) were obtained from Poisson regression models comparing MI incidence rates between HIV (overall and stratified by recent and nadir CD4 count, and recent HIV RNA levels) and HIV subjects, adjusting for age, sex, calendar era, race/ethnicity, census-based socioeconomic status, smoking, alcohol/drug abuse, overweight/obesity, diabetes, hypertension, and lipid-lowering therapy. Among HIV subjects, we also evaluated the independent association of CD4, HIV RNA, and antiretroviral therapy (ART) use.
RESULTS: The study population included 22,081 HIV and 230,069 HIV subjects. The crude MI incidence rate per 100,000 person-years was 283 and 165 for HIV and HIV subjects, respectively, with an adjusted RR of 1.4 [95% confidence interval (CI): 1.3 to 1.6]. Compared with HIV subjects (reference), MI rates were similar for HIV subjects with recent CD4 ≥500 cells per microliter (RR = 1.18; 95% CI: 0.96 to 1.45) and those with nadir CD4 ≥500 cells per microliter (RR = 0.85; 95% CI: 0.55 to 1.33). Among HIV subjects, nadir CD4 was the only HIV-specific factor associated with MIs (RR per 100 cells = 0.88; 95% CI: 0.81 to 0.96), whereas recent CD4 and HIV RNA, prior ART use, and duration of protease inhibitors and nonnucleoside reverse transcriptase inhibitors were not associated with MIs.
CONCLUSION: HIV subjects with recent or nadir CD4 ≥500 cells per microliter had similar MI rates compared with HIV subjects. Lower nadir CD4, in particular, seems to be independently associated with MIs. These results strengthen recommendations for earlier ART initiation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24442222     DOI: 10.1097/QAI.0000000000000009

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  76 in total

1.  Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection.

Authors:  Rebeccah A McKibben; Joseph B Margolick; Steven Grinspoon; Xiuhong Li; Frank J Palella; Lawrence A Kingsley; Mallory D Witt; Richard T George; Lisa P Jacobson; Matthew Budoff; Russell P Tracy; Todd T Brown; Wendy S Post
Journal:  J Infect Dis       Date:  2014-10-30       Impact factor: 5.226

2.  Cardiovascular disease in HIV: traditional and nontraditional risk factors.

Authors:  Steven K Grinspoon
Journal:  Top Antivir Med       Date:  2014 Sep-Oct

Review 3.  Antiretroviral therapy: when to start.

Authors:  Christopher J Sellers; David A Wohl
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

Review 4.  Recent Insights Into Cardiovascular Disease (CVD) Risk Among HIV-Infected Adults.

Authors:  Robert C Kaplan; David B Hanna; Jorge R Kizer
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

Review 5.  Inflammation, immune activation, and cardiovascular disease in HIV.

Authors:  Eric Nou; Janet Lo; Steven K Grinspoon
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

Review 6.  Risk of coronary heart disease in patients with HIV infection.

Authors:  Markella V Zanni; Judith Schouten; Steven K Grinspoon; Peter Reiss
Journal:  Nat Rev Cardiol       Date:  2014-10-21       Impact factor: 32.419

Review 7.  Coronary Artery Disease in HIV-Infected Patients: Downside of Living Longer.

Authors:  John Charles A Lacson; Revery P Barnes; Hossein Bahrami
Journal:  Curr Atheroscler Rep       Date:  2017-04       Impact factor: 5.113

Review 8.  Managing HIV infection in patients older than 50 years.

Authors:  Jacqueline M McMillan; Hartmut Krentz; M John Gill; David B Hogan
Journal:  CMAJ       Date:  2018-10-22       Impact factor: 8.262

9.  Undetectable = Untransmittable and Your Health: The Personal Benefits of Early and Continuous Therapy for HIV Infection.

Authors:  Mark J Siedner; Virginia Triant
Journal:  J Infect Dis       Date:  2019-01-07       Impact factor: 5.226

Review 10.  Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.

Authors:  Emma Kaplan-Lewis; Judith A Aberg; Mikyung Lee
Journal:  Curr HIV/AIDS Rep       Date:  2016-10       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.